PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of iovsIOVSARVO
 
Invest Ophthalmol Vis Sci. Mar 2012; 53(3): 1169–1176.
Published online Mar 9, 2012. doi:  10.1167/iovs.11-8259
PMCID: PMC3339901
Associations among Visual Acuity and Vision- and Health-Related Quality of Life among Patients in the Multicenter Uveitis Steroid Treatment Trial
Kevin D. Frick,corresponding author1 Lea T. Drye,2 John H. Kempen,3,4,5,6 James P. Dunn,7 Gary N. Holland,8 Paul Latkany,9 Narsing A. Rao,10 H. Nida Sen,11 Elizabeth A. Sugar,2,12,13 Jennifer E. Thorne,2,7 Robert C. Wang,14 Janet T. Holbrook,2 and for the Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group15
From the 1Department of Health Policy and Management and
the 2Center for Clinical Trials, Department of Epidemiology, The Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland;
the 3Department of Ophthalmology/Scheie Eye Institute,
the 4Center for Clinical Epidemiology and Biostatistics, and
the Departments of 5Biostatistics and Epidemiology and
6Oncology, The University of Pennsylvania, Philadelphia, Pennsylvania;
the 7Department of Ophthalmology/Wilmer Eye Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland;
the 8Department of Ophthalmology/Jules Stein Eye Institute, The David Geffen School of Medicine at UCLA, Los Angeles, California;
the 9Department of Ophthalmology, New York Eye and Ear Institute, New York, New York;
the 10Department of Ophthalmology/Doheny Eye Institute, USC School of Medicine, Los Angeles, California;
the 11National Eye Institute, National Institutes of Health, Bethesda, Maryland;
the Departments of 12Oncology and
13Biostatistics, The Johns Hopkins University, Baltimore, Maryland; and
14Texas Retina Associates, Dallas, Texas.
corresponding authorCorresponding author.
Corresponding author: Kevin D. Frick, 624 N. Broadway, Room 606, Baltimore, MD 21205; kfrick/at/jhsph.edu.
15The members of the MUST Trial Research Group are listed in the Appendix.
Received July 20, 2011; Revised October 26, 2011; Revised December 2, 2011; Accepted January 3, 2012.
Purpose.
To evaluate the associations between visual acuity and self-reported visual function; visual acuity and health-related quality of life (QoL) metrics; a summary measure of self-reported visual function and health-related QoL; and individual domains of self-reported visual function and health-related QoL in patients with uveitis.
Methods.
Best-corrected visual acuity, vision-related functioning as assessed by the NEI VFQ-25, and health-related QoL as assessed by the SF-36 and EuroQoL EQ-5D questionnaires were obtained at enrollment in a clinical trial of uveitis treatments. Multivariate regression and Spearman correlations were used to evaluate associations between visual acuity, vision-related function, and health-related QoL.
Results.
Among the 255 patients, median visual acuity in the better-seeing eyes was 20/25, the vision-related function score indicated impairment (median, 60), and health-related QoL scores were within the normal population range. Better visual acuity was predictive of higher visual function scores (P ≤ 0.001), a higher SF-36 physical component score, and a higher EQ-5D health utility score (P < 0.001). The vision-specific function score was predictive of all general health-related QoL (P < 0.001). The correlations between visual function score and general quality of life measures were moderate (ρ = 0.29–0.52).
Conclusions.
The vision-related function score correlated positively with visual acuity and moderately positively with general QoL measures. Cost–utility analyses relying on changes in generic healthy utility measures will be more likely to detect changes when there are clinically meaningful changes in vision-related function, rather than when there are only changes in visual acuity. (ClinicalTrials.gov number, NCT00132691.)
Metrics evaluating quality of life (QoL) have gained importance with the introduction of cost-effectiveness analysis (CEA). CEA attempts to evaluate whether an improvement in health due to a new form of treatment is worth the cost of the treatment.1 In practice, these analyses require data on general health-related QoL, specifically measures of health utility, to be generalizable across different treatments and diseases. In patients with uveitis specifically and eye disease in general, there is a paucity of research on the relationship of general health-related QoL and health utility metrics with visual acuity, an often used and clinically important outcome for evaluating the effectiveness of treatments for ocular diseases, or vision-related functioning. Vision-related functioning is a broader measure than visual acuity, because it evaluates patients' ability to conduct activities of daily living (e.g., reading, driving, and face recognition) for which peripheral vision, and contrast and color vision, as well as visual acuity, are important.2 Previously, visual acuity and vision-related functioning have been shown to be strongly related in patients with other eye diseases,3 and QoL scores are lower in uveitis patients than in healthy controls, especially among patients with significant vision loss.4 However, the degree to which standard health utility measures change with clinically meaningful differences in visual acuity or vision-related functioning is uncertain for patients with uveitis and limited visual acuity impairment.
Studying the relationships in the path from visual acuity to visual function to generic health-related QoL (particularly health utility) for patients with uveitis specifically is worthwhile because uveitis differs from other conditions affecting visual acuity. Uveitis is a collection of approximately 30 diseases characterized by intraocular inflammation that are collectively an important cause of visual loss in the developed world.5,6 Because noninfectious uveitis often strikes at a younger age than many common eye disorders, such as cataract, macular degeneration, and glaucoma, it has a disproportionately high impact on years of potential vision lost and workplace or home-based productivity effects.7 In addition, pain is sometimes associated with uveitis that is not associated with other conditions, and visual acuity often fluctuates rather than being stable.
The Multicenter Uveitis Steroid Treatment (MUST) Trial was designed to evaluate the comparative effectiveness of a systemic treatment strategy, primarily oral corticosteroids that may be supplemented with immunosuppressive drugs, to the fluocinolone intraocular implant.8 The primary outcome of the MUST Trial is the change in best corrected visual acuity after 2 years of follow-up. The study also collected data on several QoL metrics, including self-reported vision-related functioning assessed with the National Eye Institute Visual Function Questionnaire (NEI VFQ-25), health-related QoL assessed with the Medical Outcomes Study 36-Item Short Form (SF-36), and health utility assessed with the EuroQoL EQ-5D questionnaire. We present the associations between measures of vision (visual acuity and vision-related function) and the more general measures of QoL and heath utility that were obtained at enrollment in the MUST trial. Our objective, for patients with uveitis, was to test relationships between (1) visual acuity and specific elements of visual function; (2) visual acuity and summary measures of visual function and generic health related QoL; (3) visual function and the QoL measures, to allow for possible mediation; and (4) specific elements of visual function and health-related QoL, to further explore relationships from the third test.
The MUST Trial
The methods for the MUST Trial have been presented elsewhere.8 In brief, it was a randomized comparative effectiveness trial of the fluocinolone intraocular implant versus standardized systemic administration of corticosteroids supplemented with corticosteroid-sparing immunosuppressive drugs, as appropriate for the treatment of noninfectious intermediate, posterior, and panuveitis. Eligible patients had intermediate, posterior, or panuveitis, for which systemic treatment with oral corticosteroids was indicated in one or both eyes, there were no contraindications for treatment with either strategy, and vision was at least hand motion in the affected eye. Patients (n = 255) were enrolled at 23 clinical centers in the United States (21 centers), United Kingdom, and Australia from December 2005 through December 2008. Informed consent was obtained for all randomized patients. Institutional review boards approved the trial at each clinical and resource center. The trial was conducted in accordance with the Declaration of Helsinki and is a registered clinical trial.
Measures
At enrollment, each study participant's uveitis was classified by type as intermediate, posterior, or panuveitis. Measurements were made of visual acuity, self-reported vision-related function, and self-reported health-related QoL and health utility. Best-corrected visual acuity was measured in standard letters using the Early Treatment for Diabetic Retinopathy Study (ETDRS) logarithmic charts9 and was reported in terms of the number of lines read (i.e., dividing the standard letters by 5). For example, a difference of one line corresponds to the difference in Snellen visual acuity between 20/20 and 20/25 or between 20/160 and 20/200. Participants were also classified into three functional vision categories based on best corrected acuity in the better-seeing eye. The categories were 20/40 or better (driving vision),10 20/41 to 20/199, and 20/200 or worse (legal blindness).11
Self-reported vision-related function was measured using the National Eye Institute Visual Function Questionnaire (NEI VFQ-25).2,12 This 25-item questionnaire is used to generate a single composite score that ranges from 0 to 100, with 100 being the maximum visual function; a 4- to 6-point difference is considered clinically meaningful.13 The overall composite score is the mean of the subscale scores for general vision; ocular pain; near activities; distance activities; driving; color vision; peripheral vision; and vision-specific social functioning (e.g., seeing facial expressions), mental health (e.g., frustration or embarrassment), role difficulties, and dependency on others to perform visual tasks.
Health utility was measured with the EuroQol questionnaire, which is composed of two metrics. The first is the EQ-5D, a five-question measure of health utility based on societal preferences, a method generally preferred for cost-effectiveness analyses.14,15 Five questions ask about anxiety/depression, pain, mobility, usual activities, and self-care (essentially activities of daily living). For each question a respondent indicates that he or she does not experience the problem, experiences it moderately, or experiences it severely. The scores range from a maximum of 1 (not having any of the problems) to lower than 0, where an overall score of 0 is the health utility of death; a difference of 0.06 to 0.07 is considered clinically meaningful.16,17 Utilities for the United States were developed in a study of several thousand respondents in which each person was asked to make tradeoffs among health states; hence, the utilities are based on societal preferences. The second measure was the EQ-Visual Analog Scale (VAS), a single item on which the individual indicates a personal valuation of current health on a vertical thermometer labeled from 0 to 100. It is a measure of personal health state valuation and not a measure of vision. For the EQ-VAS, 100 is the best health state imaginable, and 0 is the worst health state imaginable; a difference of 7 is considered clinically meaningful.16 This personal valuation of health is shaped by what individuals think may be the worst imaginable health state and is not based on trade-offs.
The SF-36 was used to measure health-related QoL and produces a normative score that is not based on tradeoffs.18 The SF-36 responses are coded as scores for eight domains (physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health) as well as separate physical and mental component summary scores (referred to as PCS and MCS, respectively). The score is scaled to a population norm, with a mean of 50 and an SD of 10; a difference of 3 to 5 points is considered clinically meaningful for the PCS scale.19
Analyses
Median and interquartile ranges were calculated for all the EuroQoL, SF-36, and VFQ-25 composite scores as well as for the SF-36 and VFQ-25 subscale scores. The Kruskal-Wallis test was used to compare the distributions of the scores between patients with intermediate uveitis and those with posterior or panuveitis.
Regression models were used to evaluate the relationship between (1) visual acuity and self-reported vision-related function, (2) visual acuity and health-related QoL, and (3) vision-related function and health-related QoL. The measurement of visual acuity used was the best corrected visual acuity in the better-seeing eye. Similar models were created for best corrected visual acuity in the worse-seeing eye, but results are not shown here. Self-reported vision-related function was measured by the VFQ-25, and health-related QoL was measured by the EuroQoL and SF-36 questionnaires. Analyses were restricted to individuals able to read letters on visual acuity charts (i.e., eliminating hand motion only), which excluded a single individual from the better eye analysis. All multivariate regression models controlled for age, sex, race/ethnicity, and education. We explored controlling for the presence of a chronic, systematic, comorbid condition. As the adjustment did not alter the results substantially, we did not include the indicator in the final model.
Ordinary linear regression was used to construct the models described above when the outcome measure was normally distributed (i.e., for the outcome of the VFQ-25 composite and all VFQ-25 subscale scores except for the vision-specific social functioning scale). Robust linear regression using an M estimator with Tukey's biweight function20 was used to construct the models for which the outcome measure was skewed (i.e., the VFQ-25 vision-specific social functioning scale, the SF-36 PCS and MCS, and the EuroQol EQ-VAS). For analyses in which the EQ-5D index score was the outcome measure, the scores were grouped into quartiles and proportional odds logistic regression was used to estimate associations. This approach was chosen because more than one in four participants had the maximum EQ-5D score of 1.0 (i.e., perfect health, with no limitations in any of the five domains) and the remainder of the distribution of EQ-5D scores was highly skewed toward the maximum.
To further explore the relationship between vision-related function and health-related QoL, Spearman correlation coefficients were used to estimate the strength of association between VFQ-25 (composite and the 12 domains) and the SF-36 component summary scores (PCS and MCS) or the EQ-5D or EQ-VAS scores.
The characteristics of the 255 study participants have been published elsewhere.8 Briefly, the population was predominantly white (56%) and female (75%), with an average age of 46 years (interquartile range, 34–56 years). Most (62%) had posterior or panuveitis and 89% had bilateral uveitis; 80% had no systemic disease associated with their uveitis diagnosis. At enrollment, the median time from the initial diagnosis of uveitis was 3.8 years (interquartile range, 1.2–8.0 years). The median visual acuities in the better- and worse-seeing eyes were 78 (20/25 Snellen equivalent) and 59 (20/63 Snellen equivalent) standard letters, respectively (Table 1). Only 79 (31%) of the participants had a best corrected visual acuity in the better-seeing eye worse than driving vision (Snellen equivalent <20/40 or <70 letters), and 12 (5%) had a best corrected visual acuity worse than legal blindness (Snellen equivalent of ≤20/200 or ≤35 letters).
Table 1.
Table 1.
Visual Acuity and Questionnaire Scores of the Uveitis Participants at Baseline
The median overall composite score for self-reported vision-related functioning as measured by the VFQ-25 was 62; median subscale scores ranged between 45 for vision-specific mental health and 100 for color vision.
Median EQ-5D and EQ-VAS values for study participants were 0.8 and 80, respectively, with no significant differences between participants with intermediate versus those with posterior or panuveitis. The SF-36 summary scores and subscale scores medians were close to population norms of 50, ranging from a low median of 48 for general health to the high median of 55 for emotional role function.
A 1-line better visual acuity score (5 standard letters higher) in the better-seeing eye was predictive of higher subscale scores (P ≤ 0.001; Table 2) with the exception of the general health subscale score (P = 0.99; Table 2) and of a higher score in the overall VFQ-25 composite score (3.65 points on average; Table 3). Better visual acuity in the better-seeing eye also predicted higher scores on two of the four general measures of QoL: EQ-5D and SF-36 PCS but not EQ-VAS or SF-36 MCS (Table 3). When participants were classified into three functional categories based on visual acuity in the better eye (20/40 or better, 20/41–20/199, or 20/200 or worse), there were strong positive associations (P < 0.0001) with the median VFQ-25, SF36-PCS, and EQ-5D scores. The median SF36-PCS was 51, 47, and 34 for those functional visual acuity categories, respectively, and median EQ-5D scores were 80, 75, and 70, respectively. These functional categories were not associated with SF-36 MCS (P = 0.75) or EQ-VAS scores (P = 0.11). In analyses in which worse-eye acuity was the independent predictor, results were similar but associations were weaker (data not shown).
Table 2.
Table 2.
Associations between Visual Acuity in the Better-Seeing Eye and the NEI VFQ-25 Subscale Scores in Patients with Uveitis
Table 3.
Table 3.
Associations between Visual Acuity in the Better-Seeing Eye and Scores of Overall VFQ-25, SF-36, and EuroQoL Questionnaires in Patients with Uveitis
The ability of the NEI VFQ-25 composite score, the measure of vision-related function, to predict general health-related QoL and health utility measures was also evaluated. On average, patients who reported higher scores on the VFQ-25 composite score had higher scores for the EQ-VAS, SF-36 PCS, and SF-36 MCS (P < 0.001; Table 4). For the EQ-5D, a higher composite score on the VFQ-25 was associated with increased odds of a better health state (i.e., being in a higher quartile of EQ-5D).
Table 4.
Table 4.
Associations between the NEI VFQ-25 Composite Score and SF-36 and EuroQol Questionnaires in Patients with Uveitis
Correlations between the VFQ-25 composite and subscale scores and visual acuity and the EQ-5D, EQ-VAS, and SF-36 component scores are summarized in Table 5. The correlations between the VFQ-25 subscales and the EQ5D and SF-36 scales were in general in the range of what is considered a moderate correlation (ρ = 0.3–0.5) with a few strong correlations (ρ ≥ 0.5).21 The strongest correlation was between the VFQ-25 general health and the EQ-VAS (ρ = 0.70, 95% confidence interval [CI] 0.64–0.76). All the VFQ-25 subscales correlated at least moderately with the EQ-5D score (correlations ranging from ρ = 0.31–0.52). Most of the VFQ-25 subscales (all but general vision, driving, and color vision) also correlated moderately with the SF-36 PCS. In contrast, only the general health, vision-specific mental health, and vision-specific dependency VFQ-25 subscales correlated moderately with the EQ-VAS score and the SF-36 MCS, which is consistent with the overall lower correlation between the VFQ-25 composite score and EQ-VAS and SF-36 MCS.
Table 5.
Table 5.
Spearman Correlation Coefficients between QoL Scales for Patients with Uveitis
Our results are for a population with, on average, minimal impairment in visual acuity in the better eye (median best corrected visual acuity of 20/25 Snellen equivalent). However, our patients reported more significant impairment in vision-related function (mean visual function score = 60), similar to patients with macular edema or with choroidal neovascularization13 and well below a mean score of over 90 in patients without eye disease.2,22 The general QoL measures were within U.S. population norms for SF-36 scores. The EQ-5D median score of 0.80 fell between scores of individuals who ranked their health as good (0.84) or fair (0.71).23 The median EQ-VAS was 80, close to population norms for men and women age 30 to 60 years (VAS 85 to 90, respectively).24
Visual acuity in the better eye was predictive of vision-related function scores. For the well-established clinical difference of two lines on an ETDRS chart (e.g., 20/20 Snellen to 20/32 Snellen), visual acuity was predictive of a greater than 6-point (2 × 3.56) higher vision-related function score, which is considered to be clinically meaningful. There were more modest positive associations between visual acuity in the better eye and two measures of overall health (SF36 PCS and EQ-5D). These associations were more evident when patients were grouped into functional categories on the basis of visual acuity in the better eye, indicating that these generic measures are sensitive to functional differences in visual acuity.
Our finding of a statistically significant relationship between visual acuity in patients with uveitis and self-reported vision-related function replicates findings reported previously in populations with uveitis and other eye diseases. In India, researchers used an instrument reflecting visual function (similar to the NEI-VFQ but consisting of 33 items in Tamil) and found that it was related to visual acuity and responsive to treatment.25 Gardiner et al.26 found that binocular visual acuity was associated with vision-related function but that the visual acuity in neither the better nor the worse eye was associated with vision-related function, when analyzed in a step-wise regression approach. Our patients showed similar associations between visual acuity in the better eye and NEI-VFQ score (ρ = 0.66) and similar mean overall vision-related function score as those of patients with macular degeneration, choroidal neovascularization, diabetic retinopathy, and age-related macular degeneration,13,27 and their mean score was markedly reduced from the mean NEI-VFQ score of patients without ocular disease.16
Murphy et al.28,29 found that change in visual acuity in the worse-seeing eye correlated only moderately with a change in vision-related functioning and that there was no association between change in vision-related functioning and of change in visual acuity in the better-seeing eye. Our current evaluation is cross-sectional, and so we could not evaluate dynamic associations. However, we did find that associations were typically stronger for visual acuity in the better-seeing eye. It is possible that change in vision-related function with change in visual acuity, which may be more dramatic in the worse-seeing eye, is associated more strongly with the worse-seeing eye, whereas the cross-sectional associations of vision-related function are more related to visual acuity in the better eye. However, if the overall state of an individual is more strongly associated with vision in the better-seeing eye because the better-seeing eye is a stronger determinant of functionality, our focus on analysis of visual acuity in the better eyes is warranted.
Miserocchi et al.4 found that visual acuity was related to the SF-36-measured QoL of patients with chronic noninfectious uveitis on systemic immunosuppressive treatment. Our results showed a weaker association of visual acuity with SF36 PCS than theirs did and we found a statistically significant but weak relationship between visual acuity and the EQ-5D score. Polack et al.30 and van Nispen et al.31 have also demonstrated a direct association between poor visual acuity and worse EQ-5D scores in older populations with visual impairment due to cataract or other ocular disease. Our results are also consistent with a study that addressed a slightly different question, estimation of the relationship between the EQ-5D and self-reported blindness compared with self-reported normal vision32 This study showed that the difference in score between blindness and normal vision was 0.07—also suggesting a small-magnitude but consistent statistically significant relationship between visual acuity and health utility.
Associations between self-reported vision-related function score and general health-related QoL including health utility measures were stronger than associations of visual acuity with these more general measures. Self-reported vision-related function captures different aspects of vision-related health and well-being and may be able to integrate multiple components, such as peripheral vision and color vision, that contribute to good vision, but are not captured by visual acuity measurements. Schiffman et al.33 found a relationship between the NEI-VFQ and the PCS and MCS of the SF-36 in patients with uveitis. Furthermore, we established a similar strong association of vision-related function with the EQ-5D scores and thereby extend the prior finding to include health utility measures, which are common in cost-effectiveness studies.
One way to extend the findings in this study in the future would be to consider subgroups of patients, particularly those who may be the target of clinical guideline recommendations. For example, patients with a high degree of ocular pain, or patients with panuveitis as opposed intermediate uveitis or patients with unilateral as opposed to bilateral uveitis may be the focus of specific recommendations. We performed analyses comparing groups by their response to a question about any ocular pain on the VFQ-25 and found little difference in the relationship between visual acuity and generic health related QoL. In the future, this issue could be examined in greater detail with additional questions focusing on specific aspects of ocular pain. For example, chronic pain may influence the relationship between visual acuity and QoL more than acute pain. Performing analyses of the relationship between visual acuity, visual function, and generic health-related QoL and understanding how this would affect the interpretation of cost-effectiveness results (for which each of the outcomes listed may be used as outcomes depending on the resource allocation question being addressed) is important.
The major limitations of our evaluation are that it was a cross-sectional analysis and may not reflect temporal associations among the measures and that most of our patients had no notable visual acuity impairment. Nevertheless, our cross-sectional findings suggest that vision-related function is a stronger predictor of meaningful differences in a general health-related QoL measure than is visual acuity. However, our population had relatively good visual acuity, and so findings may not generalize to patients who present initially with low visual acuity. Furthermore, patients with persistently low vision may make accommodations for poor visual acuity that weaken the association with general health-related QoL. Finally, the study's external validity is intended to generalize only to the uveitis patients who were eligible for the consideration of the implant as a part of their treatment.
These results suggest that cost-utility analyses relying on changes in generic healthy utility measures will be more likely to detect changes when there are clinically meaningful changes in vision-related function rather than when there are only changes in visual acuity. In this regard, self-reported vision-related function may be a promising proxy for utility of cost-effectiveness studies for treatments of uveitis and other eye diseases, and, at a minimum, should always be considered as a measure of treatment effect.
Appendix
Participating Clinical Centers
Duke University, Durham, NC: Glenn J. Jaffe (Director), Michael Cusick, and Justis Ehlers. Former members: Claxton Baer, Sai Chavala, Pouya Dayani, Muge Kesen, Alex Melamud, Jawad A. Qureshi, Robert F. See, Cindy Skalak, Adrienne Williams Scott, and Robert K. Shuler.
Emory University, Atlanta, GA: Sunil Srivastava (Director) and Alicides Fernandes. Former members: Deborah Gibbs and Daniel F. Martin.
Johns Hopkins University, Baltimore, MD: James P. Dunn (Director), Ellen Arnold, Jeff Boring, Diane M. Brown, Alison G. Livingston, Kisten Nolan, and Terry Reed. Former members: Marie-Lynn Belair, Stephen G. Bolton, Joseph B. Brodine, Lisa M. Brune, Anat Galor, Adam Jacobowitz, Meera Kapoor, Sanjay Kedhar, Henry A. Leder, Yavette Morton, George B. Peters, Priscilla Soto Ricardo Stevenson, Michelle Tarver-Carr, Yue Wang, and Stephen Kim.
Massachusetts Eye Research and Surgery Institute, Cambridge, MA: C. Stephen Foster (Director), Angelica Contero, Linda Bruner, Kayleigh Fitzpatrick, David M. Hinkle, Jyothir Johnson, Danielle Marvell, and Jennifer Pinto. Former members: Sarah Acevedo, Fahd Anzaar, Tom Cesca, Karina Q. Lebron, Chandra Morgan Nita Patel, Janet Sprague, and Taygan Yilmaz.
National Eye Institute, Bethesda, MD: H. Nida Sen, (Director), Denise Cunningham, Darryl Hayes, Dessie Koutsandreas, Nupura Krishnadev, Theresa Larson, Annal D. Meleth, Richard Mercer, Robert B. Nussenblatt, Patti R. Sherry, Gregory L. Short, Wendy Smith, and Alana Temple. Former members: Allison Bamji, Hanna Coleman, Geetaniali Davuluri, Lisa Faia, Chloe Gottlieb, Guy V. Jirawuthiworavong, Julie C. Lew, Dominic Obiyor, Cheryl H. Perry, Natalia Potapova, Eric Weichel, Keith J. Wroblewski, and Steven Yeh.
New York Eye and Ear Infirmary, New York, NY: Paul A. Latkany (Director), Jason Badamo, Jenny Gallardo, Monica Lorenzo-Latkany, Robert Masini, Susan Morell, Ann Nour, Meredith Sanchez, and Kate Steinberg. Former members: Kenneth M. Boyd, Jacek Jarczynski, and Mirjana McGrosky.
Royal Victorian Eye & Ear Hospital, East Melbourne, Australia: Richard J. Stawell (Director), Lisa Breayley, Julie Ewing, Carly D'Sylva, Lauren Hodgson, Ignatios Koukouras, Lyndell Lim, Cecilia Ling, Rachel McIntosh, Andrew Newton, Richard Smallwood, and Ehud Zamir. Former members: Nicola Hunt, Lisa Jones, and Suzanne Williams.
Rush University Medical Center, Chicago, IL: Pauline T. Merrill (Director), Pam Hulvey, Elaine Kernbauer, Scott Toennessen, and Denise L. Voskuil-Marre. Former members: Bruce Gaines, Christina Giannoulis, Heena S. Khan, and Sarah J. Levine.
Texas Retina Associates, Dallas, TX: Robert C. Wang (Director), Hank Aguado, Sally Arceneaux, Kimberly Cummings, Gary E. Fish, Keith Gray, Nick Hesse, Susie Howden, Diana Jaramillo, Michael Mackens, Karin Mutz, and Brenda Sanchez. Former members: Jean Arnwine and David Callanan.
United Kingdom Institute of Ophthalmology, London, UK: Susan Lightman (Director), Timothy Stubbs, Simon Taylor, and Hamish Towler. Former member: Kate Edwards.
University of California at Los Angeles, Los Angeles, CA: Gary N. Holland (Director), Robert D. Almanzor, Jose Castellanos, Jean Pierre Hubschman, Ann K. Johiro, Michael A. Kapamajian, Ralph D. Levinson, and Susan S. Ransome. Former members: Christine R. Gonzales, Anurag Gupta, and Peter J. Kappel.
University of California at San Diego, San Diego, CA: William R. Freeman (Director), Denine E. Cochran, Igor Kozak, Vivian Nguyen, Stephen F. Oster, and Debbie Powell. Former members: Tom Clarkc, Joshua Hedaya, Tiara Kemper, Jacqueline M. LeMoine, Megan E. Loughran, Luzandra Magana, Francesca Mojana, and Victoria Morrison.
University of California at San Francisco, San Francisco, CA: Todd P. Margolis (Director), Nisha Acharya, David Clay, Claire M. Khouri, Mary Lew, Jay Stewart, and Ira G. Wong. Former member: Salena Lee.
University of Illinois at Chicago, Chicago, IL: Debra A. Goldstein (Director), Marcia Niec, Misel Ramirez, and Howard H. Tessler. Former members: Catherine E. Crooke and Dimitry Pyatetsky.
University of Miami, Miami, FL: Janet L. Davis (Director), Thomas Albini, Aura Pacini, and David A. Pinto. Former members: Daniela Castaño, Macy Ho, Jaclyn L. Kovach, Susan Pineda, Richard C.-S. Lin, Jackie K.-D. Nguyen, Kimberly E. Stepien, and Claudia Teran.
University of Michigan, Ann Arbor, MI: Susan G. Elner (Director), Rebecca Brown, Linda Fournier, Julie R. Gothrup, Richard Hackel, Moella Hesselgrave, Robert Prusak, and Stephen J. Saxe. Former members: Melissa Bergeron, Reneé Blosser, Carrie Chrisman-McClure, and Deanna Sizemore.
University of Pennsylvania, Philadelphia, PA: John H. Kempen (Director), Jim Berger, Joan DuPont, Sheri Grand, Dawn McCall, Albert M. Maguire, Laurel Weeny, Daniel Will, and Wei Xu. Former members: Tim Hopkins and Monique McRay.
University of South Florida, Tampa, FL: Peter Reed Pavan (Director), JoAnn Leto, Lori Mayor, Kim McDonald, Scott E. Pautler, Wyatt Saxon, and Judy Soto. Former members: Maria Ortiz and Dee Dee Szalay.
University of Southern California, Los Angeles, CA: Amani Fawzi, (Director), Lupe Cisneros, Elizabeth Corona, Jackie Douglass, Dean Eliott, Margaret Padilla, and Narsing A. Rao. Former members: Alexia Aguirre, Lawrence Chong, Rahul Khurana, Jennifer Lim, Rachel Mead, Sylvia Ramos, and Julie H. Tsai.
University of Utah, Salt Lake City, UT: Albert Vitale (Director), Paul S. Bernstein, Bonnie Carlstrom, James Gilman, Sandra Hanseen, Paula Morris, Diana Ramirez, and Kimberley Wegner.
Virginia Eye Consultants, Norfolk, VA: John D. Sheppard (Director), Brianne Anthony, Lisa Franklin, Krista Hamelin, Stephen V. Scoper, Jeanette Fernandez, Lisa Felix-Ken, and Rebecca Marx. Former members: Nancy Crawford, Rebecca De La Garza, R. Denise Cole, Jen Martin, Gregory Schultz, Joseph Webb, and Pamela Yeager.
Vitreoretinal Consultants, Houston, TX: Rosa Y. Kim (Director), Matthew S. Benz, David M. Brown, Eric Chen, Richard H. Fish, Shayla Hay, Jame Majo, Laura Shawver, and Tien P. Wong.
Washington University, St. Louis, MO: P. Kumar Rao (Director) and Rhonda Weeks. Former members: Rajendra S. Apte, Kevin J. Blinder, Pam Light, Gaurav K. Shah, and Russell VanGelder.
Committees
Executive Committee: Douglas A. Jabs (Chair), Michael M. Altaweel, Janet T. Holbrook, John H. Kempen, and Natalie Kurinij.
Steering Committee: Douglas A. Jabs (Chair), Robert D. Almanzor, Michael M. Altaweel, Diane Brown, James P. Dunn, James Gilman, Janet T. Holbrook, Gary N. Holland, John H. Kempen, Rosa Y. Kim, Natalie Kurinij, Nancy Prusakowski, and Jennifer E. Thorne. Former members: Stephen G. Bolton, Lisa M. Brune, Tom Clark, Larry Hubbard, Daniel F. Martin, and Robert B. Nussenblatt.
Data, Safety, and Monitoring Committee: Janet Wittes (Chair), William E. Barlow, Marc Hochberg, Janet T. Holbrook, Douglas A. Jabs, Natalie Kurinij, Alice T. Lyon, Michael M. Altaweel, Alan G. Palestine, Lee S. Simon, and Harmon Smith. Former member: James T. Rosenbaum.
Surgical Quality Assurance Committee: John H. Kempen (Chair), James P. Dunn, and Glenn J. Jaffe. Former member: Daniel F. Martin.
Medical Therapy Quality Assurance Committee: Jennifer E. Thorne (Chair), Nisha Acharya, Douglas A. Jabs, John H. Kempen, Paul A. Latkany, Robert B. Nussenblatt, and Albert Vitale. Former member: Russell VanGelder.
Visual Function Quality Assurance Committee: Robert D. Almanzor (Chair), Judith Alexander, Jeffrey A. Boring, Deborah Gibbs, Salena Lee, and Jennifer E. Thorne (Advisor). Former member: Wai Ping Ng.
Glaucoma Committee: David S. Friedman (Chair), Anna Adler, Alyce Burke, Janet T. Holbrook, Joanne Katz, John H. Kempen, Nancy Prusakowski, Susan Reed, and Jennifer E. Thorne. Former members: Nicholas Cohen, Sanjukta Modak, Wai Ping Ng.
Statistical Analysis Committee: Elizabeth A. Sugar (Chair), Lea Drye, Kevin Frick, Janet T. Holbrook, JoAnn Katz, Thomas Louis, Mark L. Van Natta. Former members: Sanjukta Modak and David Shade.
Resource Centers
Chairman's Office: Mount Sinai School of Medicine, New York, NY: Douglas A. Jabs (Study Chairman), Yasmin Hilal, Melissa A. Nieves, Karen Pascual, and Jill S. Slutsky. Former members: Maria Stevens, and Colby Glomp.
University of Pennsylvania, Philadelphia, PA: John H. Kempen (Study Vice-Chairman).
Coordinating Center, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD: Janet T. Holbrook, (Director), Anna Adler, Judith Alexander, Jeff Boring, Alyce Burke, Karen Collins, John Dodge, Lea Drye, Cathleen Ewing, Kevin Frick, David S. Friedman, Rosetta Jackson, Joanne Katz, Andrea Lears, Hope Livingston, Thomas Louis, Curtis Meinert, Jill Meinert, Vinnette Morrison, Deborah Nowakowski, Nancy Prusakowski, Dave Shade, Rochelle Smith, Karen Steuernagle, Elizabeth A. Sugar, Jennifer E. Thorne, James Tonascia, Mark L. Van Natta, and Richard Zheng. Former members: Paul Chen, Nicholas Cohen, Sanjukta Modak, Wai Ping Ng, Weijiang Shen, Charles Shiflett, and Ada Tieman.
Fundus Photograph Reading Center, University of Wisconsin, Madison, WI: Michael M. Altaweel, Wendy K. Benz, Geoffrey Chambers, Debra J. Christianson, Amitha Domalpally, Jacquelyn Freund, Vonnie Gama, Sapna Gangaputra, Kathleen E. Glander, Anne Goulding, Jeffrey M. Joyce, Christina N. Kruse, Dawn J. Myers, Susan Reed, James L. Reimers, Amy Remm, Ruth A. Susman, Dennis Thayer, Erika Treichel, Kelly J. Warren, Sheila M. Watson, James K. White, and Tara Wilhelmson. Former members: Margaret A. Fleischli, Dennis Hafford, Susan E. Harris, Larry D. Hubbard, Kristine A. Johnson, Lauren Nagle, Gwyn E. Padden-Lechten, Alyson Pohlman, Peggy Sivesind, Mary K. Webster, and Grace Zhang.
National Eye Institute, Bethesda, MD: Natalie Kurinij.
Footnotes
Supported by National Eye Institute Collaborative Grants EYU10EY014655, EYU10EY014660, and EY014656; Research to Prevent Blindness (RPB); and the Paul and Evanina Mackall Foundation. JHK was an RPB James S. Adams Special Scholar Award recipient during the time the study was conducted. JET is a recipient of the RPB Sybil Harrington Special Scholar Award. Bausch & Lomb provided support to the study in the form of donation of a limited number of fluocinolone acetonide implants for patients randomized to implant therapy who were uninsured or otherwise unable to pay for implants, but did not otherwise support the study. A representative of the National Eye Institute participated in the conduct of the study, including the study design and the collection, management, analysis, and interpretation of the data, as well as in the review and approval of the manuscript.
Disclosure: K.D. Frick, None; L.T. Drye, None; J.H. Kempen, None; Alcon (C), Lux Biosciences (C), Sanofi-Pasteur (C); J.P. Dunn, None; G.N. Holland, None; P. Latkany, None; N.A. Rao, None; H.N. Sen, None; E.A. Sugar, None; J.E. Thorne, Allergan (C); R.C. Wang, None; J.T. Holbrook, None
Reprint requests: Douglas A. Jabs, MUST Chairman's Office, Department of Ophthalmology, Mount Sinai School of Medicine, One Gustave L. Levy Place, Box 1183, New York, NY 10029-6574; douglas.jabs/at/mssm.edu.
1. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996.
2. Mangione CM, Lee PP, Gutierrez PR, et al. Development of the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol. 2001;119:1050–1058. [PubMed]
3. Submacular Surgery Trials Research Group Health- and vision-related quality of life among patients with choroidal neovascularization secondary to age-related macular degeneration at enrollment in randomized trials. Am J Ophthalmol. 2004;138:91–108. [PubMed]
4. Miserocchi E, Modorati G, Mosconi P, Colucci A, Bandello F. Quality of life in patients with uveitis on chronic systemic immunosuppressive treatment. Ocul Immunol Inflamm. 2010;18:297–304. [PubMed]
5. Doesschate J. Causes of blindness in The Netherlands. Doc Ophthalmol. 1982;52, 279–285. [PubMed]
6. National Advisory Eye Council Vision Research. A National Plan. 1983–1987. Bethesda, MD: National Institutes of Health, Public Health Service, US Department of Health and Human Services; 1983.
7. Durrani OM, Meads CA, Murray PI. Uveitis: a potentially blinding disease. Ophthalmologica. 2004;218(4):223–236. [PubMed]
8. Multicenter Uveitis Steroid Treatment Trial Research Group, Kempen JH, Altaweel MM, Holbrook JT, Jabs DA, Sugar EA. The multicenter uveitis steroid treatment trial: rationale, design, and baseline characteristics. Am J Ophthalmol. 2010;149(4):550–561. [PMC free article] [PubMed]
9. Klein R., Klein BE, Moss SE, DeMets D. Inter-observer variation in refraction and visual acuity measurement using a standardized protocol. Ophthalmology 1983;90(11):1357–1359. [PubMed]
11. Office of the Federal Register, National Archives and Records Administration. 71 FR 67037—Revised medical criteria for evaluating visual disorders. http://www.gpo.gov/fdsys/pkg/FR-2006-11-20/pdf/06-9236.pdf. Published November 20, 2006. Effective February 20, 2007 Accessed February 17, 2011.
12. Cole SR, Beck RW, Moke PS, Gal RL, Long DT. The National Eye Institute Visual Function Questionnaire: experience of the ONTT: Optic Neuritis Treatment Trial. Invest Ophthalmol Vis Sci. 2000;41(5):1017–1021. [PubMed]
13. Suner IH, Kokame GT, Yu E, Ward J, Dolan C, Bressler NM. Responsiveness of NEI VFQ-25 to changes in visual acuity in neovascular AMD: validation Studies from two phase 3 clinical trials. Invest Ophthalmol Vis Sci. 2009;50:3629–3655. [PubMed]
14. Dolan P. Modeling valuations for EuroQol health states. Med Care. 1997;35(11):1095–1108. [PubMed]
15. Shaw JW, Johnson JA, Coon SJ. US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care. 2005;43(3):203–220. [PubMed]
16. Pickard AS, Neary MP, Cella D. Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health Qual Life Outcomes. 2007;5:70. [PMC free article] [PubMed]
17. Walthers SJ, Brazier JE. Comparison of minimally important differences for two health utility measures: EQ-5D and SF-6D. Qual Life Outcomes. 2005;14:1523–1532. [PubMed]
18. McHorney CA, Ware JE, Jr, Raczek AE. The MOS 36-Item Short-Form Health Survey (SF-36): II, psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care. 1993;31(3):247–263. [PubMed]
19. Walters SJ, Brazier JE. What is the relationship between the minimally important differences and health state utility values? The case of the SF-6D. Health Qual Life Outcomes. 2003;1:4. [PMC free article] [PubMed]
20. Hampel FR, Ronchetti EM, Rousseeuw PJ, Stahel WA. Robust Statistics: The Approach Based on Influence Functions. New York: Wiley; 1986.
21. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed Mahwah, NJ: Lawrence Erlbaum; 1988.
22. Hirneiâ C, Schmid-Tannwald C, Kernt M, Kampik A, Newbauer AS. The NEI VFQ-25 vision-related quality of life and prevalence of eye disease in a working population. Graefes Arch Clin Exp Ophthalmol 2010;248:85–92. [PubMed]
23. Nyman JA, Barleen NA, Dowd BE, Russell DW, Coons SJ, Sullivan PW. Quality-of-life weights for the US population: self-reported health status and priority health conditions by demographic characteristics. Med Care. 2007;45:618–628. [PubMed]
24. Hanmer J, Lawrence F, Anderson JP, Kaplan RM, Fryback DG. Report of the nationally representative values for non-institutionalized US adult population for 7 health-related quality of life scores. Med Decis Making. 2006;26:391–400. [PubMed]
25. Venkataraman A, Rathinam SR. A pre- and post-treatment evaluation of vision-related quality of life in uveitis. Indian J Ophthalmol. 2008;56(4):307–312. [PMC free article] [PubMed]
26. Gardiner AM, Armstrong RA, Dunne MC, Murray PI. Correlation between visual function and visual ability in patients with uveitis. Br J Ophthalmol. 2002;86(9):993–996. [PMC free article] [PubMed]
27. Johns D, Hollands S, Hollands H, Schweitzer K, Almeida D, Sharma S. Quality of life amongst American vs. Canadian patients with retinal diseases. Curr Opin Ophthalmol. 2010;21:227–232. [PubMed]
28. Murphy CC, Greiner K, Plskova J, Frost NA, Forrester JV, Dick AD. Validity of using vision-related quality of life as a treatment end point in intermediate and posterior uveitis. Br J Ophthalmol. 2007;91(2):154–156. [PMC free article] [PubMed]
29. Murphy CC, Hughes EH, Frost NA, Dick AD. Quality of life and visual function in patients with intermediate uveitis. Br J Ophthalmol. 2005;89(9):1161–1165. [PMC free article] [PubMed]
30. Polack S, Eusebio C, Fletcher A, Foster A, Kuper H. Visual impairment from cataract and health related quality of life: results from a case-control study in the Philippines. Ophthalmic Epidemiol. 2010;17(3):152–159. [PubMed]
31. Van Nispen RMA, de Boer MR, Hoeijmakes JGJ, Ringens PJ, van Rens GHMB. Co-morbidity and visual acuity are risk factors for health-related quality of life decline: five month follow-up EQ-5D data of visually impaired older adults. Health Qual Life Outcomes. 2009;7(18)1477–7525. [PMC free article] [PubMed]
32. Frick KD, Gower EW, Kempen JH, Wolff JL. Economic impact of visual impairment and blindness in the United States. Arch Ophthalmol. 2007;125(4):544–550. [PubMed]
33. Schiffman RM, Jacobsen G, Whitcup SM. Visual functioning and general health status in patients with uveitis. Arch Ophthalmol. 2001;119(6):841–849. [PubMed]
Articles from Investigative Ophthalmology & Visual Science are provided here courtesy of
Association for Research in Vision and Ophthalmology